133 - Focused Plenary
Results of Gynecologic Oncology Group (GOG) 229K: a phase II trial of BIBF-1120 for women with advanced, recurrent, or metastatic endometrial carcinoma
Monday, March 24, 2014: 4:05 PM
Ballroom B/C (Tampa Convention Center)
D. S. Dizon1, M. Sill2, J. M. Schilder3, K. F. McGonigle4, Z. Rahman5, D. S. Miller6, D. G. Mutch7 and K. K. Leslie8
1Massachusetts General Hospital/Harvard University, Boston, MA, 2Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, 3Indiana University School of Medicine, Indianapolis, IN, 4Northwest Hospital & Medical Center, Women's Cancer Care of Seattle, Seattle, WA, 5St. Francis Hospital and Medical Center, Hartford, CT, 6University of Texas Southwestern Medical Center, Dallas, TX, 7Washington University School of Medicine, St. Louis, MO, 8University of Iowa Hospitals and Clinics, Iowa City, IA
